Abstract:Inhibition of histone deacetylase (HDAC) has been regarded as a potential therapeutic approach for treatment of multiple diseases including cancer. Based on pharmacophore model of HDAC inhibitors, a series of quinoline-based N-hydroxycinnamamides and N-hydroxybenzamides were designed and synthesized as potent HDAC inhibitors. All target compounds were evaluated for their in vitro HDAC inhibitory activities and anti-proliferative activities and the best compound 4a surpass Vorinostat in both enzymatic inhibitory activity and cellular anti-proliferative activity. In terms of HDAC isoforms selectivity, compounds 4a exhibited preferable inhibition for class I HDACs, especially for HDAC8, the IC50 value (442 nM) was much lower than that of Vorinostat (7468 nM). Subsequently, we performed class I & IIa HDACs whole cell enzyme assay to evaluate inhibitory activity in whole cell context. Compounds 4a and 4e displayed much better cellular activity for class I HDACs than that for class IIa HDACs, which indicated that 4a and 4e might be potent class I HDAC inhibitors. Meanwhile, flow cytometry analysis showed that compound 4a and 4e can promote cell apoptosis in vitro.

Design, Synthesis and Biological Evaluation of Urea-Based Benzamides Derivatives As HDAC Inhibitors

Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.

Design, Synthesis and Biological Evaluation of Novel Isoindolinone Derivatives As Potent Histone Deacetylase Inhibitors.

Design, synthesis and antitumor activity evaluation of novel benzamide HDAC inhibitors

Design, Synthesis and Biological Evaluation of Isoquinoline-Based Derivatives As Novel Histone Deacetylase Inhibitors

Design, Synthesis and Biological Evaluation of Quinoline Derivatives As HDAC Class I Inhibitors.

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Design, Synthesis and Biological Evaluation of 4-Anilinothieno[2,3-d]pyrimidine-based Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors.

Design, Synthesis and Bioactivity Evaluations of 8-Substituted-quinoline-2-carboxamide Derivatives As Novel Histone Deacetylase (HDAC) Inhibitors.

Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.

Design, synthesis and bioevaluation of novel N-heterocyclic hydroxamic acids as histone deacetylase inhibitors and their antitumor activity study

Design, Synthesis and Biological Evaluation of Tyrosine-Based Hydroxamic Acid Analogs As Novel Histone Deacetylases (hdacs) Inhibitors.

Design, Synthesis and Biological Evaluation of Thienopyrimidine Hydroxamic Acid Based Derivatives As Structurally Novel Histone Deacetylase (HDAC) Inhibitors

N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.

Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors

Design, Synthesis and Preliminary Activity Assay of 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Derivatives As Novel Histone Deacetylases (hdacs) Inhibitors.

Design, Synthesis, and Biological Evaluation of Histone Deacetylase Inhibitors Derived from Erianin and Its Derivatives.

Key structural requirements of benzamide derivatives for histone deacetylase inhibition: design, synthesis and biological evaluation

Design, Synthesis, and Biological Evaluation of 1, 3-Disubstituted-pyrazole Derivatives As New Class I and IIb Histone Deacetylase Inhibitors

Design, synthesis, and in vitro biological evaluation of novel HDAC inhibitors bearing C-1 phenyl substituted tetrahydroisoquinoline Cap moiety as anti-tumor therapeutic agents

Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.